Eyeworld

97 EW REFRACTIVE October 2018 Contact information Vukelic: sv2147@columbia.edu a clinical trial sometime in the next year. Research on PiXL, which is already available as a refractive treatment in Europe and Asia but not yet approved for use in the U.S., continues to progress as well. A pa- per session at the 2018 ASCRS•ASOA Annual Meeting included several presentations about photorefractive intrastromal crosslinking. One eval- uated the safety and efficacy of PiXL with supplemental oxygen in 40 eyes of patients who were unwilling to have laser vision correction. 2 The mean change in manifest refraction from baseline was 1.18 +/–0.5 D at 3 months postop and UDVA change was logMAR 0.526. According to this research, 78.3% of eyes were UCDVA 20/25 or better at 3 months without significant regression, hyperopic shift, endothelial cell loss, or loss of best corrected visual acuity due to haze. Another paper looked at the safety and efficacy of PiXL with supplemental oxygen with target- ed, high-dose, pulsed, accelerated application. At 6 months, the mean change in manifest refraction of the 21 eyes in 11 patients was 1.6 D from baseline; there was a 1.8 D shift in spherical equivalent from baseline. UCVA improved by a mean of four lines, and there was no sig- nificant change in endothelial cell density or number of cells. 3 Lim et al. published results in 2017 show- ing the efficacy and stability of PiXL out to 12 months for treatment of low myopia. 4 EW References 1. Wang C, et al. Femtosecond laser crosslink- ing of the cornea for non-invasive vision cor- rection. Nature Photonics. 2018;12:416–422. 2. Sachdev GS, Ramamurthy S. Photorefrac- tive intrastromal crosslinking for the treatment of low myopia. 2018 ASCRS•ASOA Annual Meeting. 3. Elling Em, Dick HB. Epithelium-on photore- fractive intrastromal CXL with supplemental ox- ygen for low myopic refractive error: six-month results. 2018 ASCRS•ASOA Annual Meeting. 4. Lim WK, et al. Epithelium-on photore- fractive intrastromal crosslinking (PiXL) for reduction of low myopia. Clin Ophthalmol. 2017;11:1205–1211. Editors' note: Dr. Vukelic has no finan- cial interests related to his comments. T e x t u r e d G r i p F o r B e t t e r C o n t r o l L i g h t w e i g h t , A l u m i n u m H a n d l e D i a m o n d - l i k e S h a r p n e s s FEATHER name is a registered trademark of FEATHER Safety Razor Co., Ltd. OASIS name & logo are registered trademarks of OASIS ® Medical, Inc. 514 S Vermont Ave, Glendora, CA 91741. LIT-SRG-Ad-AAOEWShow2018 Rev.0 9.2018 (844) 820-8940 F E AT H E R ® O p h t h a l m i c S c a l p e l s Level Up Quality. Redene Sharp. R e u s a b l e & D i s p o s a b l e From the company that brought your practice Oasis TEARS ® Email: Oasis@oasismedical.com www.oasismedical.com Learn More At AAO Booth #2600. True Surgical Solutions.

• Cover